Health Catalyst (NASDAQ:HCAT) Announces Earnings Results

Health Catalyst (NASDAQ:HCAT) released its earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02), FiscalAI reports. The firm had revenue of $74.68 million for the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.

Health Catalyst Stock Down 3.8%

NASDAQ HCAT traded down $0.07 during trading on Thursday, hitting $1.79. The stock had a trading volume of 530,433 shares, compared to its average volume of 812,365. The company has a market capitalization of $126.61 million, a PE ratio of -1.13 and a beta of 1.76. The company’s 50-day moving average price is $2.08 and its two-hundred day moving average price is $2.59. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. Health Catalyst has a 12 month low of $1.56 and a 12 month high of $5.06.

Wall Street Analysts Forecast Growth

Several analysts have commented on HCAT shares. Citigroup dropped their target price on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating for the company in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.06.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its holdings in shares of Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after buying an additional 1,793,374 shares during the last quarter. Vanguard Group Inc. increased its holdings in Health Catalyst by 2.9% during the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock worth $12,243,000 after buying an additional 119,117 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Health Catalyst by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after acquiring an additional 169,580 shares during the period. Millennium Management LLC increased its stake in shares of Health Catalyst by 2,513.3% during the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after purchasing an additional 1,528,710 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Health Catalyst by 4.3% during the 4th quarter. State Street Corp now owns 1,327,922 shares of the company’s stock worth $3,174,000 after purchasing an additional 54,168 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.